BS_15ETQ0E4
ATRT
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- ATRT
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- ATRT
- overall_survival_months
- 3.843626806833114
- age_years
- 2.419
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.614
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.597
- ALLOGRAFT_REJECTION+0.569
- INFLAMMATORY_RESPONSE+0.530
- IL6_JAK_STAT3_SIGNALING+0.528
- TNFA_SIGNALING_VIA_NFKB+0.499
- COAGULATION+0.470
- INTERFERON_GAMMA_RESPONSE+0.469
- IL2_STAT5_SIGNALING+0.450
- KRAS_SIGNALING_UP+0.445
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.549
- PROTEIN_SECRETION-0.376
- PEROXISOME-0.359
- ADIPOGENESIS-0.348
- DNA_REPAIR-0.334
- FATTY_ACID_METABOLISM-0.270
- HEDGEHOG_SIGNALING-0.210
- PI3K_AKT_MTOR_SIGNALING-0.204
- CHOLESTEROL_HOMEOSTASIS-0.168
- HEME_METABOLISM-0.145
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_1J2WQ08M | Posterior Fossa Ependymoma | — | 0.892 |
| 2 | BS_ENKG5GF3 | Neurofibroma | — | 0.892 |
| 3 | MNG653 | — | — | 0.886 |
| 4 | BS_PGHK1JRW | ATRT | — | 0.882 |
| 5 | TCGA-BT-A3PK-01A-21R-A220-07 | — | — | 0.878 |
| 6 | BS_3J85TTZM | MPNST | — | 0.876 |
| 7 | BS_AHEFXG7W | Med | Medulloblastoma | 0.871 |
| 8 | SRR1319816 | GTEX | — | 0.864 |
| 9 | TCGA-BT-A42E-01A-11R-A23W-07 | — | — | 0.863 |
| 10 | TCGA-63-6202-01A-11R-1820-07 | — | cohortA1 | 0.861 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.614 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.597 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.569 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.530 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.528 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.499 | Inavolisib | — uncovered |
| COAGULATION | 0.470 | Binimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.469 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.450 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.445 | Inavolisib | — uncovered |
| COMPLEMENT | 0.441 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.375 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.333 | Inavolisib | — uncovered |
| APOPTOSIS | 0.292 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.286 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.259 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.258 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.251 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.241 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.236 | Idelalisib | — uncovered |